Blueprint Medicines (BPMC) Tops Q1 EPS by 307c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
Tweet
Share
E-mailGet Alerts BPMC Hot Sheet
Join SI Premium – FREE
Blueprint Medicines (NASDAQ: BPMC) reported Q1 EPS of $1.40, $3.07 better than the analyst estimate of ($1.67). Revenue for the quarter came in at $96.12 million versus the consensus estimate of $80.89 million.
GUIDANCE:
Blueprint Medicines sees FY2024 revenue of $390-410 million, versus the consensus of $393 million.
For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Wyndham Hotels & Resorts, Inc. (WH) Tops Q3 EPS by 12c, Beats on Revenue; Offers FY26 EPS Guidance
- Getty Realty (GTY) Tops Q3 EPS by 5c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
